Study of EVP-6308 to Assess the Dose- and Concentration-dependent Displacement of [18F]MNI-659 by EVP-6308

Completed · Phase 1

Conditions studied: Healthy

In brief

This is an open-label, single-arm, multiple ascending dose Phase I study to assess the dose- and concentration-dependent displacement of \[18F\]MNI-659 \[a PET tracer targeting phosphodiesterase 10 (PDE10)\] by EVP-6308.

Key facts

Study ID

NCT02001389

Run by

FORUM Pharmaceuticals Inc

People needed

14

Starts

2013-10-01

Last updated by the study team

2014-10-10

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male or female volunteers, 18 to 50 years of age

You may not qualify if…

• Clinically significant abnormalities on physical examination, medical history, ECG , vital signs, laboratory values, or unstable medical or psychiatric illness
• Any disorder that may interfere with drug absorption.
• Clinically significant allergy or sensitivity to medications Positive test for human immunodeficiency virus (HIV) antibodies, Hepatitis B surface antigen, or Hepatitis C antibody.
• Pregnant or breast feeding.
• History of exposure to any radiation >15 mSv/year (e.g., occupational or radiation therapy) over the past year.

Where it is running

• Study site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.